Revance Therapeutics, Inc. is a biotechnology company with its global headquarters located in Nashville, Tennessee. Originally founded as Essentia Biosystems, the company develops aesthetic and therapeutic peptide-based products and maintains research and development operations.
Subscribe to see Revance Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Revance Therapeutics is a biotech company headquartered in Nashville, United States. Xcout recorded 116 job postings from Revance Therapeutics in the last 90 days, naming tools such as Salesforce, ADP, Jira.
As of 16 November 2026. Source: Xcout Intel.
Xcout recorded 116 job postings from Revance Therapeutics in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Revance Therapeutics's hiring signals →
Based on 80 job postings in the last 8 weeks (21 Sep – 15 Nov 2026), compared with 187 scale-up healthcare companies.
This describes a hiring pattern — how often Revance Therapeutics’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
A few of Revance Therapeutics's closest competitors — see the full list of competitors and alternatives →
Histogen Inc. is a biotechnology company headquartered in San Diego, California, focused on the development of regenerative medicine and novel therapeutics.
Rgenix, Inc. is a biotechnology company headquartered in New York, NY, focusing on therapeutic and oncology developments.
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Rapalogix Health, Inc. is a biotechnology company headquartered in Carlsbad, California, pioneering a new category of longevity-based skin health products.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California. The company focuses on reinventing the patient experience through innovative drug delivery technologies and global collaborations.
Orion Therapeutics, Inc. is a therapeutic and RNA therapeutics company enabled by a novel delivery platform. The company is headquartered in Knoxville, Tennessee.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Revance Therapeutics? Suggest a correction · Work at Revance Therapeutics? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.